Scientists are developing an organ chip platform that will help them to efficiently conduct preclinical drug tests of human drugs.
FREMONT, CA: There is only a limited amount of testing drugs that are approved by the U.S. Food and Drug Administration (FDA), and the number even decreases when the drug is about orphan diseases that affect few people.
The issue arises because of the improper nature of preclinical drug testing because they intentionally eliminate the toxic effects and predetermined concentrations and administrator routes before the drugs are tested on people. It cannot be presumed how appropriately the new drug affects a body just by testing it on animals, so while it is applied on the human, they have to be extra careful as they do not know how it will move within the body or affect it.
Therefore according to the researchers, to bring a solution to this enormous problem, it is necessary to become more efficient while setting the stage for the drugs that can be promising and have the ability to rule out others that are most likely to fail in human beings.
A group of scientists at TAU and Harvard has now developed a functioning comprehensive multi-Organ-on-a-Chip (Organ Chip) platform that facilitates efficient in-vitro-to-in-vivo translation (IVIVT) of human drug pharmacology.
There is a hope that this platform will help to create a gap in the present restrictions that have to be dealt with during the development of drugs by offering a reliable, relevant, and practical system for examining the medicines used for humans.
The organ chips are microfluidic tools that are created from a clear, flexible polymer. The size of the polymer is similar to a computer memory stick, and it has two parallel hollow channels that are divided by a porous membrane and independently perfused with the cell-type specific media. The layer not only permits the two compartments to commune with each other but also exchange molecules such as cytokines and growth factors. It can also exchange drug products and drugs that are produced by organ-specific metabolic activities.